Hansoh Pharmaceutical (03692) Announces MHRA Approval of Aumetinib Mesylate Tablets (Aumseqa®) for NSCLC Treatment in the UK

Hansoh Pharma (03692) announced that the innovative drug Aumseqa® (generic name: Almonertinib Mesylate Tablets) developed by the Group has been approved for marketing by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Aumseqa® is indicated as monotherapy for: First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations, and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.